Takeda’s Qdenga gets India approval, targets H1 2027 private-market launch
Takeda’s Qdenga has become the first dengue vaccine approved in India. The two-dose vaccine is indicated for people aged 4–60 and is expected to reach private healthcare channels in H1 2027, supported by manufacturing partnerships with Biological E and Indian Immunologicals.
Takeda’s Qdenga became the first dengue vaccine approved in India and is targeted for private-healthcare availability in H1 2027. Takeda and Biological E are expanding manufacturing, with capacity support of up to 50 million doses annually.
Why this matters
With no related recent signals listed, Qdenga’s approval is Takeda Pharmaceutical India’s first tracked step toward India’s private dengue-vaccine market.
Retail-company signals are accelerating, up 937500% QoQ.